SEC Form 4 · accession 0000914190-15-000294
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Norman David Eansor
Officer — SVP - Novus Biologicals
Period of report
Aug 7, 2015
Accepted (ET)
Aug 11, 2015 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 4,469 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $108.49 | Aug 7, 2015 | A | 12,500 | A | — | Aug 7, 2022 | Common Stock | 12,500 | 12,500 | D |
| Stock Option (Right to Buy)F5 | $108.49 | Aug 7, 2015 | A | 6,250 | A | — | Aug 7, 2022 | Common Stock | 6,250 | 6,250 | D |
| Restricted Stock UnitsF4,F5 | — | Aug 7, 2015 | A | 1,000 | A | — | — | Common Stock | 1,000 | 1,000 | D |
| Stock Option (Right to Buy)F2 | $94.35 | holding | — | — | — | — | Aug 12, 2021 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Includes 3,333 shares of restricted stock units that vest 1,667 shares on 7/1/16 and 1,666 shares on 7/1/17 (previously reported on Table II).
- F23,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- F33,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- F4Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F5Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.